GPR39 and atherosclerosis: Interestingly, GPR39-C3 treatment attenuates oxidized low-density lipoprotein (ox-LDL)-induced attachment of monocytes to endothelial cells by inhibiting p65/nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) transcription, attenuating the first step of inflammatory plaque formation and atherosclerosis [84].